These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25721040)

  • 1. CD30: seeing is not always believing.
    Blum KA
    Blood; 2015 Feb; 125(9):1358-9. PubMed ID: 25721040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
    Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
    Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
    Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
    Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
    Rothe A; Sasse S; Goergen H; Eichenauer DA; Lohri A; Jäger U; Bangard C; Böll B; von Bergwelt Baildon M; Theurich S; Borchmann P; Engert A
    Blood; 2012 Aug; 120(7):1470-2. PubMed ID: 22786877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CD30 as a biomarker to predict response to brentuximab vedotin.
    Xu ML; Acevedo-Gadea C; Seropian S; Katz SG
    Histopathology; 2016 Jul; 69(1):155-8. PubMed ID: 26648051
    [No Abstract]   [Full Text] [Related]  

  • 6. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
    Bartlett NL; Smith MR; Siddiqi T; Advani RH; O'Connor OA; Sharman JP; Feldman T; Savage KJ; Shustov AR; Diefenbach CS; Oki Y; Palanca-Wessels MC; Uttarwar M; Li M; Yang J; Jacobsen ED
    Leuk Lymphoma; 2017 Jul; 58(7):1607-1616. PubMed ID: 27868471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
    Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
    J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure.
    Nathwani N; Krishnan AY; Huang Q; Kim Y; Karanes C; Smith EP; Forman SJ; Sievers E; Thomas SH; Chen RW
    Leuk Lymphoma; 2012 Oct; 53(10):2051-3. PubMed ID: 22369501
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
    Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
    Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
    Rinaldi I
    Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin.
    Ansell SM
    Blood; 2014 Nov; 124(22):3197-200. PubMed ID: 25293772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
    Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
    Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.
    Berger GK; McBride A; Lawson S; Royball K; Yun S; Gee K; Bin Riaz I; Saleh AA; Puvvada S; Anwer F
    Crit Rev Oncol Hematol; 2017 Jan; 109():42-50. PubMed ID: 28010897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
    Al-Rohil RN; Torres-Cabala CA; Patel A; Tetzlaff MT; Ivan D; Nagarajan P; Curry JL; Miranda RN; Duvic M; Prieto VG; Aung PP
    J Cutan Pathol; 2016 Dec; 43(12):1161-1166. PubMed ID: 27531242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Scarisbrick JJ
    Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brentuximab vedotin in anaplastic large cell lymphoma.
    Skarbnik AP; Smith MR
    Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.
    Ramos CA; Ballard B; Zhang H; Dakhova O; Gee AP; Mei Z; Bilgi M; Wu MF; Liu H; Grilley B; Bollard CM; Chang BH; Rooney CM; Brenner MK; Heslop HE; Dotti G; Savoldo B
    J Clin Invest; 2017 Sep; 127(9):3462-3471. PubMed ID: 28805662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.
    Poston JN; Fromm JR; Rasmussen HA; Shustov AR; Libby EN; Smith SD; Gooley T; Gopal AK
    Br J Haematol; 2019 Jul; 186(1):159-162. PubMed ID: 30592026
    [No Abstract]   [Full Text] [Related]  

  • 20. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
    Bhatt G; Maddocks K; Christian B
    Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.